Uso de biológicos en el LES: una revisión de la evidencia desde una perspectiva clínica.

Autores
Categoría Revisión sistemática
RevistaRheumatology (Oxford, England)
Año 2016
Cargando información sobre las referencias
With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.
Epistemonikos ID: d0eaa596e5924d96b41aadad18541aef47ed6c3d
First added on: Jun 13, 2017